Inflarx N V
Officers & Directors
Niels Riedemann has served as Executive Director and Chief Executive Officer since 2007. Renfeng Guo has been Executive Director and Chief Scientific Officer since 2007. Thomas Taapken was appointed Chief Financial Officer in 2020. Camilla Chong became Chief Medical Officer in 2023. Derval O’Carroll was appointed Senior Vice President, Global Head of Regulatory Affairs and Compliance in 2023.
Nicolas Fulpius has been Non-Executive Director and Chairman of the Board since 2007. He is a co-founder of InflaRx, with a background in venture capital and entrepreneurship, holding an MBA from the University of St. Gallen and a Master of Science in Engineering from Stanford University. Richard Brudnick has served as Non-Executive Director since 2019. He was previously Chief Business Officer at Prime Medicine, Inc., and held senior roles at Codiak BioSciences, Bioverativ, and Biogen. He holds bachelor’s and advanced degrees from MIT. Mark Kubler has been a Non-Executive Director since 2015. He is a partner at GIG Ltd., has served on boards of Swiss companies, and holds master’s degrees in business, economics, and law from the University of St. Gallen. Anthony Gibney was appointed Non-Executive Director in 2021. He is a biotechnology executive and former investment banker with over 25 years of experience advising biotech companies in the US and Europe.
Inflarx N V currently has 65 employees.
News about Inflarx N V Key Personnel |
1. Article for :
InflaRx, a pioneering biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system, is set to make a significant announcement concerning its upcoming development plans for a potential game-changer, INF904. Alongside this, the company will release its much-awaited financial and operating results for the fourth quarter and full year of 2023. The details will be presented during a conference call on March 21, 2024, providing a platform for InflaRx to showcase their progress and strategic vision.
INF904, an orally available C5aR inhibitor, has generated considerable excitement in the pharmaceutical industry due to its potential to serve a...
|
|
